POPULARITY
Happy Halloween!
Welcome to The Trip Report Podcast, a production of Beckley Waves, a Psychedelic Venture Studio.Last week on the podcast, I spoke with Dr. Carlene MacMillan, psychiatrist and Chief Medical Officer of Osmind, about the FDA's rejection of MDMA Assisted Therapy. That conversation focused on some of the problems with the application, including potentially missing data, inaccurate or unreported adverse events, and the general uncertainty that both the Advisory Committee and FDA itself had with the work Lykos submitted.Today's conversation addresses the matter from another perspective, namely the inadequacy of the current regulatory regime for evaluating treatments that challenge the current epistemological paradigm and come from “outsider” organizations.To make sense of this, I asked Nick Gillespie, Editor at Large of Reason Magazine, to come on the podcast to discuss the matter. To say that Nick is critical of the FDA would be an understatement.His position is that the latent mission of the FDA and other regulatory agencies is to maintain the existing power structures and commercial interests of the organizations they regulate rather than to protect public health, ensure public trust, or facilitate the availability of new treatments.His views challenge mainstream narratives of both the right and the left, which makes him the perfect guest as we delve into the complexities of drug regulation, the FDA's role in approving psychedelic therapies, and the broader implications for personal autonomy in today's world.In this episode, we explore:* The challenges of navigating the FDA's regulatory process for novel therapies like MDMA-assisted psychotherapy.* The increasingly confusing political and ideological landscape * Outdated and ossified regulatory institutions* The prospect of individual states taking over regulatory responsibilities from the federal government* The cultural and political dynamics that shape public opinion on psychedelics and other controlled substances.* The evolving landscape of personal freedom in the context of healthcare and drug use.* And much more.And now, I bring you my conversation with Nick Gillespie.Listen to the episode on Substack, Spotify, Google or Apple.Credits:* Hosted by Zach Haigney * Produced by Zach Haigney, Erin Greenhouse, and Katelin Jabbari* Find us at thetripreport.com* Follow us on Instagram, Twitter, LinkedIn and YouTubeTheme music by MANCHO Sounds, Mixed and Mastered by Rollin Weary This is a public episode. If you would like to discuss this with other subscribers or get access to bonus episodes, visit www.thetripreport.com
Welcome to a special episode of The Trip Report Podcast, a production of Beckley Waves, a Psychedelic Venture Studio.Today, we're dissecting the FDA's rejection of Lykos Therapeutics MDMA Assisted Therapy with Dr. Carlene MacMillan MD, a Harvard-trained psychiatrist and Chief Medical Officer at Osmind.In her role at Osmind, Dr. MacMillan has the unique experience of helping practices across the country adopt new treatment modalities like Ketamine, Spravato, and Transcranial Magnetic Stimulation. And through her work with professional societies like the American Psychiatric Association and the Clinical TMS Society, she has been involved in developing policies, treatment codes, and access to new interventional psychiatric treatments. This background and experience made her a great person to speak with about the FDA decision, the most pivotal development this nascent field has seen.In this special dispatch, we dive deep into the potential rationale and aftermath of the FDA's decision, as well as the implications for the future of psychedelic therapies, research, and commercialization. In this conversation, we discuss:* The allegations of research misconduct* The difficulty the FDA and Advisory Committee had with the therapeutic component of the trial* The complexities of psychiatric trial designs and the importance of reliable data.* The role of real-world evidence and post-marketing data in evaluating new treatments.* The challenges of integrating new therapies into mainstream healthcare.* The future of psychiatric treatments, including neuromodulation and other emerging therapies.* And much more.And now, I bring you my conversation with Dr. Carlene MacMillan.Listen to the episode on Substack, Spotify, Google or Apple.Credits:* Hosted by Zach Haigney * Produced by Zach Haigney, Erin Greenhouse, and Katelin Jabbari* Find us at thetripreport.com* Follow us on Instagram, Twitter, LinkedIn and YouTube* Theme music by MANCHO Sounds, Mixed and Mastered by Rollin Weary This is a public episode. If you would like to discuss this with other subscribers or get access to bonus episodes, visit www.thetripreport.com
In this conversation, Kyriakos Eleftheriou is joined by Lucia Huang , CEO of Osmind. They discuss the founding story, the problem in mental health, fundraising, and many more. Chapters 00:00 Intro 03:03 Founding Story 11:31 User Feedback 21:19 The Y Combinator Experience 23:14 Go-to-Market Strategy 23:50 Tracking Patient Outcomes and Interim Feedback 25:02 Building a Full Electronic Health Record System 29:20 Fundraising and Choosing Investors 31:36 Selecting Good Investors and the Importance of Operator Background 33:41 Creating Scarcity Mindset in Fundraising 35:56 Hiring for Values and Building Company Culture 41:30 Scaling the Team and Transitioning to a Management Role 44:06 Exploring the Potential of Psychedelic Medicine 48:06 Looking backwards from 100 years in the future
The Frontier Psychiatrists started as a Creator First show on the ill-fated clubhouse app. One of our favorite guests was the remarkable (Jeremy Fox, LPC), an EMDR therapist with a passion for working with men around their actual problems. One of those is the loss of normative friendships among men—15% of men report no close friendships at all. This corrosion of close relationships is an accelerating problem for both individual men and society.Today's episode of the podcast includes both the video above and pushes the audio to the podcast feed!Prior writing on the value of friendships and what we can do about that includes articles such as:It's important to have FriendsFriends: A How-To GuideMatthew Perry was ClassyA Conflict of Interest Disclosure Regarding My Picks for SXSWThe Future of Brain Health?Announcing: May 5th, 2024…Rapid Acting Mental Health Treatment NYC 2024(Eventbrite Link)It's a night of thrilling conversations about the future of mental health. It features speakers from…Videra, MDHub, Osmind, Neurosigma, iRxReminder, and…Lykos Theraputics!More info to come…but it's the second IRL The Frontier Psychiatrists event, and we could not be more excited to have you! This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit thefrontierpsychiatrists.substack.com/subscribe
Join Carlene MacMillan, chief medical officer at Osmind, to explore the evolving role of primary care physicians in addressing mental health challenges, particularly in the context of emerging therapies like ketamine. We delve into misconceptions surrounding ketamine use, factors to consider when prescribing it, and its potential benefits when combined with psychotherapy. Carlene MacMillan is chief medical officer, Osmind, a public benefit corporation dedicated to aiding clinicians and researchers in advancing life-saving mental health treatments. In this role, she concentrates on product development, growth initiatives, and medical affairs. Dr. MacMillan is also a co-founder of Fermata Health, an interventional psychiatry practice located in Brooklyn, NYC. She can be reached on X @CarleneMac. She discusses the KevinMD article, "Ketamine for mental health conditions: What every primary care physician needs to know." Careers by KevinMD is your gateway to health care success. We connect you with real-time, exclusive resources like job boards, news updates, and salary insights, all tailored for health care professionals. With expertise in uniting top talent and leading employers across the nation's largest health care hiring network, we're your partner in shaping health care's future. Fulfill your health care journey at KevinMD.com/careers. VISIT SPONSOR → https://kevinmd.com/careers Discovering disability insurance? Pattern understands your concerns. Over 20,000 doctors trust us for straightforward, affordable coverage. We handle everything from quotes to paperwork. Say goodbye to insurance stress – visit Pattern today at KevinMD.com/pattern. VISIT SPONSOR → https://kevinmd.com/pattern SUBSCRIBE TO THE PODCAST → https://www.kevinmd.com/podcast RECOMMENDED BY KEVINMD → https://www.kevinmd.com/recommended GET CME FOR THIS EPISODE → https://earnc.me/cd5ryA Powered by CMEfy.
On this episode of Raise the Line, we'll introduce you to a relatively new company in the digital health space focused on treatment-resistant mental health patients, which constitute about 30% of people in the US with a mental health diagnosis. Our guest is Jimmy Qian, the co-founder and president of Osmind, who believes mental health practitioners could benefit from a more data-driven approach. “We can't understand the biology of neuropsychiatry unless we get more and more multimodal data and work together as a scientific community to really understand how mental health even works, and that requires rethinking diagnosis and treatments from the ground up using data,” says Qian. As he tells host Shiv Gaglani, Osmind is sharing its data with researchers to help improve scientific understanding of hard-to-treat conditions and has already published two studies with Stanford, including the largest ever real-world analysis of ketamine as a treatment for depression. Check out this informative conversation to learn how Osmind's platform is also giving patients the opportunity to provide real-time information on how they're doing between visits and helping providers smooth out their workflow.Mentioned in this episode: https://www.osmind.org/
Dr. Molly Maloof, physician and entrepreneur, kind of the female pendant to Andrew Huberman, is finally on the show today! Molly Maloof is one of the first people I read about, in terms of the new psychedelic space. Molly is one of the people in the psychedelic space, who marries science, medicine and psychedelics. Working on future topics in psychedelics, he has a pretty impressive track record of engagements in the new health space. She is the Founder & CEO, Adamo Bioscience, working on biological, psychological, psychedelic, and technological solutions to become the foremost scientific company perpetuating the power of love. She was a lecturer at Stanford University, taught the course “Live Better Longer: Enhancing Healthspan for Longer Lifespan” within the Wellness Department of the School of Medicine. (She received the highest student ratings in the department) She is the founder of DrMolly.co, a modern health and wellness media brand that inspires, educates, and motivates people to make the right lifestyle choices so they can actualize their potential. She is the medical advisor: for Neurohacker, Drugs over Dinner, Osmind ect. Now, Molly has just released her new book “The Spark Factor”. “A breakthrough program for women to revive their lost energy and vitality, developed by a leading biohacker and physician. In her book, Molly talks about the spark we are all looking for on a daily basis. With cutting-edge biohacking insights, strategies for personalized nutrition, hormonal health and stress management, The Spark Factor is the book women have been waiting for to help them reclaim their vitality and achieve lasting health.” Molly and I talk about supplement overkill and pill fatigue the redefinition of stress and health the possibility to address sexual trauma with the support of psychedelics sexual psychedelic therapy for the masses, the limitations of classic couples therapy and why we share so many phantasies around love drugs and love potions. More Info: https://drmolly.co/
Our guest for this episode is Dr. Carlene MacMillan, an expert in mental health and VP of Clinical Innovation at Osmind. Carlene's area of focus is exploring innovative mental health treatments for anxiety and depression, among other conditions. She talks with James about some of these treatments such as psychedelic assisted therapy and Transcranial Magnetic Stimulation (TMS) therapy. Over the course of the conversation, Carlene helps us to define some of these newer therapies and addresses some of the misconceptions around them.
Jacob sits down with Lucia Huang, co-founder and CEO of Osmind, to discuss new psychedelic and neuromodulation mental health treatments, how Osmind is furthering research around them, and what's next for the space.
YC-backed mental health and psychedelic startup Osmind raises $40 million Series B. Watch, listen or read today.
In this episode of #healthTechDeals Jess DaMassa is hoping Matthew Holt disappears, possibly on Elon Musk's rocket to Mars. Matthew just wants him to buy Chelsea FC. And then there's actual funding deals for Osmind ($40m), Turquoise Health ($20), Mahmee ($9) and Simplifed which got $6m despite having Matthew help!
In this episode of #healthTechDeals Jess DaMassa is hoping Matthew Holt disappears, possibly on Elon Musk's rocket to Mars. Matthew just wants him to buy Chelsea FC. And then there's actual funding deals for Osmind ($40m), Turquoise Health ($20), Mahmee ($9) and Simplifed which got $6m despite having Matthew help!
In today's episode, we chat with Lucia Huang, the CEO and co-founder of Osmind, an electronic health record software system for treatment resistant mental health practices that is already in over 300 clinics. In this episode, we discuss:How Osmind makes data-driven decisions Osmind's quick growth in only 2 yearsWhat it will take for insurance to cover ketamine therapy, as well as other psychedelic therapiesCreated by Greg Kubin and Matias SerebrinskyHost: Matias Serebrinsky & Greg KubinProduced by Jonathan Davis & Zack FrankMarketing by DaisyMae VanValkenburghFind us at businesstrip.fmFollow us on Instagram and Twitter!Theme music by Dorian LoveAdditional Music: Distant Daze by Zack Frank
Laurie McGraw is speaking with Inspiring Woman Lucia Huang, CEO and CoFounder of Osmind, a company focused on the future of mental health with an EHR as well as an engagement and outcomes ...
In this episode, we're super excited to have Lucia Huang, CEO and Co-Founder at Osmind, the operating system for neuropsychiatry. Founded in 2020, Osmind provides software and data for precision mental health to help the 22M Americans with treatment-resistant mental health conditions. Prior to founding Osmind, Lucia was the Director of Operations and Finance at Verge Genomics, a next generation neuroscience drug discovery company. In July 2021, Osmind raised a $15M Series A led by Future Ventures! We're a proud early supporter at Pear VC as well.
In this episode of Freedom with NFT's Carlene MacMillan MD shares with us: How to be a part of an NFT Community and why it's important How to care for your mental health while diving into NFTs How to leverage your expertise in the NFT community About Carlene MacMillan MD: Carlene MacMillan, M.D. is the co-founder/CEO of Brooklyn Minds and fast becoming the go to psychiatrist in the metaverse. She is a Harvard-trained adult and child psychiatrist who pioneers team-based and tech-enabled mental health care that individuals with complex psychiatric concerns live meaningful lives. Dr.MacMillan became known for her role as the co-host of New Frontiers, an award-winning show on Clubhouse where mental health experts weigh in on aspects of our culture. It was on this show she first connected with the Blazed Cats Team, who are donating hundreds of thousands of dollars to Mental Health America. This helped her realize the potential of the NFT space when it comes to mental health. She then joined the LostBoyNFT project as their Psychiatrist-in-Residence and is active in a number of other NFT projects that prioritize doing good. Outside of the metaverse, she is an internationally recognized leader in Mentalization Based Treatment, collaborating with leaders at the Anna Freud National Centre for Children and Families. She is on the Clinical Advisory board of Osmind and a member of the Ketamine Taskforce for Access to Safe Care and Insurance Coverage. She is on the Clinical TMS Society Insurance Committee and is the co-Chair of the American Academy of Child and Adolescent Psychiatry Consumer Issues Committee. In this episode of Freedom with NFTs, we talked about how she discovered the big role of mental health in the NFT space, how she leveraged her areas of expertise and contributed for the good in the metaverse. Connect with Carlene MacMillan MD: Twitter: https://twitter.com/CarleneMac Website: https://brooklynminds.com/ Connect with your host, Lauren Turton: Twitter: https://twitter.com/LaurenTurton_ Facebook: https://www.facebook.com/thelaurenturton Instagram: https://www.instagram.com/laurenturton/ Website: https://freedomwithnfts.com
OVERVIEW: Jason A. Duprat, Entrepreneur, Healthcare Practitioner, and Host of the Healthcare Entrepreneur Academy podcast talks with Laura Meaney, DNAP, CRNA, and Co-Founder of Focused Infusion Therapy. Laura talks about the steps she took to open her practice and offers advice for anyone interested in starting a ketamine clinic. EPISODE HIGHLIGHTS: In 2019, Laura got her doctorate in anesthesia. Her doctoral thesis was on ketamine and protocols for treatment-resistant depression. Her practice, Focused Infusion Therapy, is located in Arizona and has been open since October 2020. Her business partner had the capital to launch. They started small and now have plans to open satellite clinics in the central Phoenix area. Laura shares how she found her medical director, a physician from a local hospital. He reviews charts and consults. She also shares the steps she and her business partner took to open their practice—from purchasing equipment to renting a place to set things up. Laura talks about how they overcame the challenge of launching a website and what marketing methods they used to promote their business. The American Association of Nurse Anesthesiology and the American Psychiatric Nurses Association released a joint statement that CRNAs should be collaborating with mental health clinicians if they're treating mental health patients. Laura admits some patients have experienced side effects after ketamine infusions, such as nausea and headaches. She's worked with them to manage these side effects. Focused Infusion Therapy also offers IV therapy, which she believes is a great complimentary service to ketamine. It's so rewarding to see people feeling better. Laura's father suffered from depression and chronic pain. After having ketamine therapy treatments, she said he smiles more and enjoys playing golf. Laura is on a mission to spread the good word about ketamine everywhere she can. Her advice for anyone concerned about the challenges of opening your practice: Suck it up and stick it out. It's about the mission and not the money. 3 KEY POINTS: The Ketamine Academy helped Laura better understand how to achieve her goal of opening her ketamine practice. It only took her and her business partner four to five months to launch Focused Infusion Therapy. Her mission is to bring health and wellness to all aspects of a patient's life through ketamine infusions and IV therapy. Laura wants to help people get back to their lives and have happier days. Laura advises hiring people who can fill in the gaps when you open a practice - hire for what you don't know. TWEETABLE QUOTES: “Collaboration is key.” - Laura Meaney “I have a lot of hats but I also have a lot of help.” - Laura Meaney “If you don't know, you need to hire somebody who does know.” - Laura Meaney RESOURCES: Focused Infusion Therapy website: https://focusedinfusionwickenburg.com/ Collaborating Docs website: https://collaboratingdocs.com/ Ketamine Media website: https://ketaminemedia.com/ Osmind website: https://www.osmind.org/ Ketamine Academy: https://www.ketamineacademy.com/ #HealthcareEntrepreneurAcademy #healthcare #entrepreneur #entrepreneurship #podcast #ketamine #ketamineclinic #ketaminetherapy #ivtherapy #practiceowner #startup
OVERVIEW: Jason A. Duprat, Entrepreneur, Healthcare Practitioner, and Host of the Healthcare Entrepreneur Academy podcast talks with Shelley Christ, DNP, PMHNP, and Co-Owner of Hope for Healing. Shelley discusses her journey as a business owner and the steps she took to open her practice. She also offers advice for people who want to start their own practice. EPISODE HIGHLIGHTS: Shelley is a board-certified psychiatric mental health nurse practitioner with a Doctor of Nursing Practice degree and 30 years of experience as an RN. Hope for Healing opened in January 2021 in Avon, Connecticut. Once she completed the Ketamine Academy course, it took Shelley three months to open the practice. The course taught Shelley about scope of practice, state laws, malpractice insurance, as well as staffing and supply requirements. Shelley had owned a home health business so she was already familiar with policies and procedures, hiring people, and managing employees. Her goal for Hope for Healing is to create a spa-like atmosphere with a warm, welcoming environment and to ensure a high level of customer service. This includes someone always being available to answer the phone so patients can schedule appointments with no waiting. Comfort touches include massage and anti-gravity chairs, drinks, snacks, and blankets. Shelley talks about different models for cognitive behavioral therapy (CBT). She shares her own experiences with treatment-resistant depression which eventually led her to try ketamine therapy. Her advice to people who want to start their own practice: If you can't go without the income from your work, go slow. Invest in a good marketing agency that understands what you're trying to get across. When it comes to staffing, Shelley knew a lot of people already. She hired new staff through word-of-mouth and placed ads on LinkedIn and Indeed. Services are private pay. She does provide patients with a superbill that they can submit to their insurance companies. Shelley is passionate about her vision and the people she cares for. Her business focus is to attract, love, and nurture people. 3 KEY POINTS: Shelley's previous experiences as a business owner, coupled with what she has learned from the Ketamine Academy course, have helped her launch and run her own practice. Hope for Healing follows a holistic approach, combining low-dose ketamine infusions, medication management, and a short-term CBT program. After her own positive experience with ketamine, Shelley feels her purpose is to help as many people as she can—people who suffer from depression, anxiety, and post-traumatic stress. TWEETABLE QUOTES: “When we make changes in the way we're thinking... we feel better and we do better.” - Shelley Christ “With ketamine - within two weeks and by my sixth treatment - I was back to myself.” - Shelley Christ “If you want to make it work, you're going to make it work.” - Shelley Christ RESOURCES: Hope for Healing: https://hopeforhealingcenter.com/ Ketamine Academy: https://www.ketamineacademy.com/ Scout Collective: https://www.scoutcollectivedigital.com/ Osmind: https://www.osmind.org/ Rate & Review: https://lovethepodcast.com/hea Subscribe & Follow: https://followthepodcast.com/hea #HealthcareEntrepreneurAcademy #healthcare #entrepreneur #entrepreneurship #podcast #ketamine #ketamineclinic #ketaminetherapy #mentalhealth #depression #cognitivebehavioraltherapy #practiceowner #startup
Hello and welcome back to Equity, TechCrunch's venture capital-focused podcast, where we unpack the numbers behind the headlines.For this week's deep dive, Alex and Natasha and Danny decided that it was time to talk about drugs. No, not like drugs for fun, but instead drugs that you might have considered fun, but are now being redirected to help bolster your health.Yep, that's our theme today. As it turns out, there are a number of startups and even nascently public companies that are pursing using drugs that we might consider recreational for serious health purposes. Which is neat, as our habit of decrying any drug that makes you feel better as immoral has likely held us back from learning quite a lot about them.Venture capital investment in psychedelic start-ups, per CB Insights, rose from sub-$100 million results in 2018 and 2019 to $346 million last year.Vice clauses, however, can pause a legitimate issue for investors who might want to cut a check in the space.From the startup angle, NUE Life Health recently raised $3.3 million, and Osmind is up to some neat stuff regarding mental health.From the public markets, Atai Life Sciences, Compass Pathways, and MindMed are the companies worth watching.Frankly this was a fun one to record, even if the topic at hand is actually rather serious. Chat Friday morning!
Hello and welcome back to Equity, TechCrunch's venture capital-focused podcast, where we unpack the numbers behind the headlines.For this week's deep dive, Alex and Natasha and Danny decided that it was time to talk about drugs. No, not like drugs for fun, but instead drugs that you might have considered fun, but are now being redirected to help bolster your health.Yep, that's our theme today. As it turns out, there are a number of startups and even nascently public companies that are pursing using drugs that we might consider recreational for serious health purposes. Which is neat, as our habit of decrying any drug that makes you feel better as immoral has likely held us back from learning quite a lot about them.Venture capital investment in psychedelic start-ups, per CB Insights, rose from sub-$100 million results in 2018 and 2019 to $346 million last year.Vice clauses, however, can pause a legitimate issue for investors who might want to cut a check in the space.From the startup angle, NUE Life Health recently raised $3.3 million, and Osmind is up to some neat stuff regarding mental health.From the public markets, Atai Life Sciences, Compass Pathways, and MindMed are the companies worth watching.Frankly this was a fun one to record, even if the topic at hand is actually rather serious. Chat Friday morning!
OVERVIEW: Jason A. Duprat, Entrepreneur, Healthcare Practitioner, and Host of the Healthcare Entrepreneur Academy podcast talks with Christi Myers, MS, EMT-P, CEO, Director, and Founder of Flow Integrative. Christi highlights the steps she took to open her practice and also talks about why it's important to focus on the patient experience. EPISODE HIGHLIGHTS: Christi has been a paramedic for the last 20 years and she's been teaching for ten years. The mental health of her students and people in the healthcare industry motivated her to open her ketamine practice in Redlands, CA in November 2020. She recently moved her clinic to Encinitas in April 2021. It was a five-month process for Christi to open her practice. She asked a physician to join her and everything unfolded during COVID. Her advice? Step in 100%! Christi credits the Ketamine Academy course for helping her understand the legal aspects of the business, as well as scope of practice. She explains the difference between assisted psychotherapy and getting a low-dose ketamine infusion. The dosing structure depends on how people cope outside of therapy. People are struggling with depression and ketamine isn't covered by insurance. So Christi created a nonprofit to help those who can't afford treatments. She credits Osmind and Caretaker for being great partners and helping her with the launch and operations of the practice. Christi was able to source partners because of her working relationships as a paramedic. Christi provides an overview of her services and what it's like to partner with a physician. Her patient experience includes providing space for patients to release emotion - for the clinic and staff to offer an open space and heart. They also provide gravity blankets to help patients feel grounded. The goal is to restore well-being using individualized, scientific-based therapeutic methods. There is no blanket approach for treating patients - it's an intimate experience for each person. 3 KEY POINTS: There's a stigma about ketamine due to recreational abuse, but it can be beneficial for treating depression and anxiety—even PTSD—if given in small doses. Christi hired an attorney to help her with the legal aspects of opening her practice. She then created two corporations, partnered with a physician, and utilized her knowledge in medicine and wellness. Christi makes sure the psychotherapy sessions are not too clinical to ensure her clients feel safe and comfortable enough to help reach a breakthrough. TWEETABLE QUOTES: “It comes down to courage of trying something essentially taboo.” - Christi Myers “[Starting your own practice] isn't easy, but it isn't challenging as long as you have pieces to rely on.” - Christi Myers RESOURCES: Flow Integrative: https://flowintegrativeketamine.com/ Osmind: https://www.osmind.org/ Caretaker: https://caretakermedical.net/ Psychedelic Spotlight Interview: https://psychedelicspotlight.com/interview-with-christi-myers/ Mental Health Support for First Responders Blog Post: https://medium.com/osmind/mental-health-support-for-first-responders-ba8e43fd464c #HealthcareEntrepreneurAcademy #healthcare #entrepreneur #entrepreneurship #podcast #ketamine #ketamineclinic #ketaminetherapy #mentalhealth #depression #PTSD #practiceowner #startup
For this week’s deep dive, Alex and Natasha dug into Danny's latest mega-project: A long, fascinating, and deeply-reported series into the world of disaster tech. It's all about the market, startups, and their backers, so it was perfect fare for our Wednesday episode, in which we dive deep into a single topic.Part 1: The most disastrous sales cycle in the worldPart 2: Data was the new oil, until the oil caught firePart 3: When the Earth is gone, at least the internet will still be workingPart 4: The human-focused startups of the hellfireWe were super curious why Danny had picked disaster tech to niche into, as we hadn't heard that much about it, frankly. But past the fact that it's a world where sales cycles can last as long as House Congressional tenures, there was quite a lot to get into:Consumer: Dorothy wants to to provide bridge loans to folks who get rekt by a hurricane. As government, and insurance money can take ages to arrive, the startup could be onto something. and Perimeter wants to take data, and help folks actually know where to go when there is am emergency.Data: Danny's deep dive into the world of data in the disaster space came with a provocative headline, but the market backs him up. In this space we took a look at Cornea, which just raised $15 million to help firefighters better understand conflagrations, and Gridware raised $5.3 million to install boxes on power lines. Very smart boxes, we should add.Mental health: We end with a riff on how companies are preparing humans to better handle disaster before and after it strikes. Alto Neuroscience, which is a stealthy startup founded by Amit Etkin, is looking to solve PTSD with brain-wave data, while NeuroFlow uses polling, and savvy collabs with practitioners to monitor emerging symptoms. Psychedelic therapeutics also might have some opportunity to shine thanks to Osmind.The series was fun to mine through, and expect Danny's byline to be all over the topic in the coming weeks. Talk soon, unless - actually especially, if - all of hell breaks loose!
For this week’s deep dive, Alex and Natasha dug into Danny's latest mega-project: A long, fascinating, and deeply-reported series into the world of disaster tech. It's all about the market, startups, and their backers, so it was perfect fare for our Wednesday episode, in which we dive deep into a single topic.Part 1: The most disastrous sales cycle in the worldPart 2: Data was the new oil, until the oil caught firePart 3: When the Earth is gone, at least the internet will still be workingPart 4: The human-focused startups of the hellfireWe were super curious why Danny had picked disaster tech to niche into, as we hadn't heard that much about it, frankly. But past the fact that it's a world where sales cycles can last as long as House Congressional tenures, there was quite a lot to get into:Consumer: Dorothy wants to to provide bridge loans to folks who get rekt by a hurricane. As government, and insurance money can take ages to arrive, the startup could be onto something. and Perimeter wants to take data, and help folks actually know where to go when there is am emergency.Data: Danny's deep dive into the world of data in the disaster space came with a provocative headline, but the market backs him up. In this space we took a look at Cornea, which just raised $15 million to help firefighters better understand conflagrations, and Gridware raised $5.3 million to install boxes on power lines. Very smart boxes, we should add.Mental health: We end with a riff on how companies are preparing humans to better handle disaster before and after it strikes. Alto Neuroscience, which is a stealthy startup founded by Amit Etkin, is looking to solve PTSD with brain-wave data, while NeuroFlow uses polling, and savvy collabs with practitioners to monitor emerging symptoms. Psychedelic therapeutics also might have some opportunity to shine thanks to Osmind.The series was fun to mine through, and expect Danny's byline to be all over the topic in the coming weeks. Talk soon, unless - actually especially, if - all of hell breaks loose!
Lucia HuangOsmindCo-founder and CEOLucia previously worked to help find cures for ALS and Parkinson's at Verge Genomics, an AI-driven neuroscience biotech startup. At Verge, she helped scale the company from seed to post-Series A. She previously invested in innovative healthcare technology companies at Warburg Pincus. Lucia started her career advising pharmaceutical companies in investment banking. Lucia graduated Yale with a B.S. in Chemistry and earned an MBA at Stanford Graduate School of Business, where she was also awarded a Certificate in Public Management and Social Innovation. At Stanford, Lucia focused her studies on healthcare and co-led the GSB Healthcare Club. Lucia is passionate about mental health and has devoted her career to improving healthcare, from life sciences to new technology innovation. www.osmind.org
Lucia and Jimmy, co-founders of Osmind, discuss psychedelic therapies for mental illness, the future of the Bay Area, and public benefit corporations. The Bioinformatics CRO is a fully distributed contract research company that serves the computational biology needs of biotechnology companies, with a focus on genomics. https://www.bioinformaticscro.com/
Would you participate in therapy that uses FDA approved psychedelics?Our guests, Lucia Huang & Jimmy Qian, are the CEO, COO, and Co-Founders of Osmind.Osmind is a Y Combinator from the Summer 2020 batch.Learn more and connect with Lucia & Jimmy:Website: https://osmind.org/LinkedIn: https://www.linkedin.com/in/luciayhuang/Email: lucia@osmind.orgLinkedIn: https://www.linkedin.com/in/jimmyjqian/Email: jimmy@osmind.orgListen to more Calls From the Future here: https://bit.ly/2STWsETTIMESTAMPS:0:03 Osmid introduction 3:20 Catamine therapy & How does Osmid make it easier 7:41 Osmid story 16:27 What is it specifically about this niche? 18:36 Where are we with this more alternative therapies? 21:03 What does the future look like? 26:17 Phenotyping 27:13 Lucia & Jimmies story 31:15 Thoughts on the future human and tech merger + Maps development 34:11 War on drugs 39:16 COVID influence on the business 43:20 Found raising experience 44:29 Treasury management & investing into Crypto 48:26 10-20 year trends for mental health industry 51:08 The journey 58:37 Mental models & mental game 1:02:06 Follow up with Lucia & Jimmy
In this episode we talk about the Ketamine Taskforce and our partnership with OSMIND. The goal of our Taskforce is to get Medicare to officially approve Ketamine as Treatment for Chronic pain and mental health. Our goal is also to extend the available research to show the effectiveness of Ketamine for treating these diagnoses. For more information on the Taskforce look for our website, Ketaminetaskforce.com --- Support this podcast: https://podcasters.spotify.com/pod/show/berkleykjones/support
Lucia Huang is co-founder and CEO of Osmind, a digital health startup working to maximize innovative treatments to mental health. Osmind provides an electronic health record software (EHR) for providers serving patients with treatment-resistant mental health conditions. Their software and analytical insights help providers optimize care and contribute to research of new diagnostics and therapies. They now serve over 22,000 patients in 135 mental health practices in the U.S. Osmind was founded in early 2020 and is backed by General Catalyst and Y Combinator. Lucia previously led business at Verge Genomics, an AI-driven neuroscience biotech startup aiming to cure ALS and Parkinson's. She previously invested in innovative healthcare technology companies at Warburg Pincus. Lucia graduated Yale with a B.S. in Chemistry and earned an MBA at Stanford Graduate School of Business, where she was also awarded a Certificate in Public Management and Social Innovation. Lucia is passionate about mental health and has devoted her career to improving healthcare, from life sciences to new technology innovation. ____________________ SHOW NOTES 1:57 - Background on Osmind 5:13 - Current landscape of ketamine / psychedelic clinics 7:08 - Lucia's personal journey with mental health 10:45 - What it's like to receive ketamine treatment, using mood trackers 14:24 - Osmind's partnership with Caretaker, a wireless patient monitor 15:51 - How research and clinical care go hand in hand 18:01 - How psychedelics can be tested in a controlled setting 19:04 - Future of psychedelics - tailored drugs vs commodities 24:03 - How Osmind is building a community for people who are treatment resistant 25:54 - How Lucia's parents have come around to her working in psychedelics 26:48 - Should psychedelics be legal 28:15 - What Lucia is excited about in the psychedelic industry ____________________ LINKS See the full show notes, transcript and YouTube clips here https://twitter.com/osmindhq https://www.instagram.com/osmindhealth/ https://www.facebook.com/osmindHQ https://www.linkedin.com/company/osmind hello@osmind.org ____________________ MIND THINGS Follow us on Twitter: @mindthingsco Subscribe to our newsletter Follow us on YouTube